



January 5, 2018

## **Radius Health to Present at the 36th Annual J.P. Morgan Healthcare Conference**

WALTHAM, Mass., Jan. 05, 2018 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), today announced that President and Chief Executive Officer, Jesper Høiland, will present a corporate update at the 36th Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2018 at 11:00 a.m. PST at the Westin St. Francis Hotel in San Francisco, California.

A live webcast of the presentation will be available by visiting the Investors section of Radius' website at <http://ir.radiuspharm.com/events.cfm>. A replay of the webcast will be archived on Radius' website for 30 days following the presentation.

### **About Radius Health**

Radius is a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases. Radius' lead product, TYMLOS (abaloparatide) injection, was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. Radius' Marketing Authorisation Application (MAA) for abaloparatide-SC for the treatment of postmenopausal women with osteoporosis is under regulatory review in Europe. The Radius clinical pipeline includes an investigational abaloparatide transdermal patch for potential use in osteoporosis; the investigational drug elacestrant (RAD1901) for potential use in hormone-receptor positive breast cancer; and the investigational drug RAD140, a non-steroidal, selective androgen receptor modulator (SARM) under investigation for potential use in hormone-receptor positive breast cancer. For more information, please visit [www.radiuspharm.com](http://www.radiuspharm.com), and follow us on [Twitter](#) and [LinkedIn](#).

### **Investor Relations Contact:**

Elhan Webb, CFA  
Email: [ewebb@radiuspharm.com](mailto:ewebb@radiuspharm.com)  
Phone: 617-551-4011